I am enrolled in an open label trial of Treprostinil via inhalation 4x daily. My use of the open label medication began in January 2023 following a year in a blind trial. By the end of 2022 symptoms of PAH had appeared. My diagnosis of IPF was made following a biopsy in June 2018. My symptoms first appeared in December 2015. I am in the…

Read more

My first symptoms were experienced in 2015, with diagnosis in June 2018, following a lung biopsy. Since then, I had taken Esbriet for one year, discontinued because of a significant Erithroderma. I have been on Ofev for 3 years to date, with the “usual” side effects which are manageable. For the last three years I have been on O2 at two… Read more

I have been enrolled in the double-blind trial of Tyvaso for IPF since early January.

The medication (or placebo, as the case may be) is received via a nebulizer that delivers a programmed number of metered doses, four times a day. The titration process begins with inhalation of 3 measured doses (4x daily), then ramps up an additional dose… Read more

IPF is typically difficult to diagnose; in my case the onset of symptoms was experienced in 2015, with the actual diagnosis in June 2018 following a lung biopsy.  Referral to an experienced Pulmonologist is essential – the earlier, the better.  Describing the progression as “mild to moderate to severe” I am currently in what is characterized as… Read more